(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from INPI

USO DE CONJUGADOS DE FÁRMACO E ANTICORPO QUE COMPREENDEM AGENTES DE INTERRUPÇÃO DE TUBULINA PARA TRATAR TUMOR SÓLIDO

ArquivadaInvention PatentPCT · US2019023516

Application data

Number

112020018948

Type

Invention Patent

Filing

03/22/2019

Publication

01/05/2021

PCT

US2019023516

Progress at the INPI

  1. Filing03/22/19
  2. Publication01/05/21
  3. Abandoned
  4. Allowance
  5. Grant
  6. In force

The application was abandoned: examination was not requested within the 36 months following the 03/22/2019 filing, the deadline set by art. 33 of the Brazilian IP Act. The technology is in the public domain in Brazil.

Talk to a specialist

Latest action published by the INPI: 09/13/2022. We update with every new RPI gazette, published weekly.

Applicants and inventors

Applicants

SEAGEN INC.

US

SEATTLE GENETICS, INC.

US

See this company's full portfolio

Inventors

A. C. (pessoa física)

US

S. G. (pessoa física)

US

Technical data

Priority claims

US

62/647,346 · 03/23/2018

US

62/658,276 · 04/16/2018

Abstract

A presente descrição se refere, em geral, a métodos para tratar tumores sólidos que compreendem administrar um conjugado de anticorpo de ligante de fármaco, em que o fármaco é um agente de interrupção de tubulina.

Prosecution history

Publications in the Brazilian Industrial Property Gazette (RPI).

Arquivamento definitivo - Art. 33 da LPI

#11.1.1

09/13/2022

RPI 2697

Arquivamento - Art. 33 da LPI

#11.1

07/05/2022

RPI 2687

Alteração de nome deferida

#25.4

05/17/2022

RPI 2680

Adição na publicação

#15.35

12/14/2021

RPI 2658

Notificação de entrada na fase nacional - PCT

#1.3

01/05/2021

RPI 2609

Alteração de dados cadastrais

#1.1

10/20/2020

RPI 2598

Patent monitoring

Track this patent in real time.

Receive alerts on INPI events, decisions, and expiry dates for your portfolio.